-
Product Insights
NewCancer Anorexia-Cachexia Syndrome – Drugs In Development, 2024
Empower your strategies with our Cancer Anorexia-Cachexia Syndrome – Drugs In Development, 2024 report and make more profitable business decisions. Cancer anorexia-cachexia syndrome is defined as progressive weight loss associated with malignancy and is characterized by loss of appetite (anorexia), skeletal muscle wasting, and reduced adipose tissue. Approximately 50% of cancer patients report abnormalities of eating behavior at the time of first diagnosis and prevalence is even higher at approximately 65%. The incidence of weight loss upon diagnosis varies greatly according...
-
Product Insights
NewOropharyngeal Cancer – Drugs In Development, 2024
Empower your strategies with our Oropharyngeal Cancer – Drugs In Development, 2024 report and make more profitable business decisions. Oropharyngeal cancer is a disease in which malignant cells form in the tissue of oropharynx. The oropharynx is the middle part of the throat and includes the base of the tongue, the tonsils, the soft palate, and the walls of the pharynx. Oropharyngeal cancers can be divided into two types: HPV-positive, which are related to human papillomavirus infection; and HPV-negative cancers, which...
-
Product Insights
NewGallbladder Cancer – Drugs In Development, 2024
Empower your strategies with our Gallbladder Cancer – Drugs In Development, 2024 report and make more profitable business decisions. Gallbladder cancer symptoms include abdominal pain, nausea and/or vomiting, jaundice, loss of appetite, fever, itchy skin, dark urine, and weight loss. Risk factors include overweight, age, family history, gallstones, gender, and choledochal cysts. Treatment includes surgery, chemotherapy, and radiation therapy. The Gallbladder Cancer drugs in development market research report provide comprehensive information on the therapeutics under development for Gallbladder Cancer, complete with...
-
Product Insights
NewNeuroendocrine Tumors – Drugs In Development, 2024
Empower your strategies with our Neuroendocrine Tumors – Drugs In Development, 2024 report and make more profitable business decisions. Neuroendocrine tumor begins in the hormone-producing cells of the body’s neuroendocrine system, which is made up of cells that are a cross between traditional endocrine cells (or hormone-producing cells) and nerve cells. Symptoms include hyperglycemia, diarrhea, loss of appetite/weight loss, thickening or lump in any part of the body, jaundice, headache, anxiety, and gastric ulcer disease. Treatments include surgery, radiation therapy, and...
-
Product Insights
NewSquamous Non-Small Cell Lung Cancer – Drugs In Development, 2024
Empower your strategies with our Squamous Non-Small Cell Lung Cancer – Drugs In Development, 2024 report and make more profitable business decisions. Squamous cell carcinoma is a subtype of non-small cell lung cancer (NSCLC) originating in the squamous cells lining the airways. It constitutes about 25-30% of all lung cancers. Linked to smoking, symptoms include persistent cough, chest pain, and breathing difficulties. Diagnosis involves imaging, biopsy, and staging to determine the cancer's extent. Treatment options depend on the stage but may...
-
Product Insights
NewRecurrent Head And Neck Cancer Squamous Cell Carcinoma – Drugs In Development, 2024
Empower your strategies with our Recurrent Head And Neck Cancer Squamous Cell Carcinoma – Drugs In Development, 2024 report and make more profitable business decisions. Recurrent head and neck squamous cell carcinoma (HNSCC) refers to the return of cancer in the head and neck region after initial treatment. HNSCC includes tumors of the oral cavity, pharynx, larynx, and other structures. Recurrence can occur locally, regionally, or distantly. Management of recurrent HNSCC depends on the specific circumstances, including the location and extent...
-
Product Insights
NewNasopharyngeal Cancer – Drugs In Development, 2024
Empower your strategies with our Nasopharyngeal Cancer – Drugs In Development, 2024 report and make more profitable business decisions. Nasopharyngeal cancer is a rare type of head and neck cancer. It starts in the upper part of throat, behind the nose, an area called the nasopharynx. The risk factors of nasopharyngeal cancer may include Epstein-Barr virus. Symptoms of nasopharyngeal cancer may include blurry or double vision, difficulty speaking including hoarseness, recurrent ear infections, face pain or numbness, headache, hearing loss, and...
-
Product Insights
NewNeuroendocrine Cancer – Drugs In Development, 2024
Empower your strategies with our Neuroendocrine Cancer – Drugs In Development, 2024 report and make more profitable business decisions. A neuroendocrine cancer, often referred as a neuroendocrine tumor (NET) or neuroendocrine neoplasm, begins in the specialized cells of the body’s neuroendocrine system. These cells have traits of both hormone-producing endocrine cells and nerve cells. They are found throughout the body’s organs and help control many of the body’s functions. Hormones are chemical substances that are carried through the bloodstream to have...